Injection of Glatiramer Acetate Depot Results in T1 and T2 Lesion Reduction in Relapsing MS.

Published Date: 01 Mar 2023

Secondary results from a phase 3 study show that patients with multiple sclerosis receiving glatiramer acetate depot therapy have significantly fewer new T1 enhancing lesions and new, enlarging hyperintense T2 lesions.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

recognizing the mechanism by which the replication of the host cell is outperformed by the skin cancer virus.

2.

High numbers of rural patients cross state lines for cancer care

3.

Watch for Psoriasis After Cancer Immunotherapy, Study Says

4.

It has been discovered that personalized dosing in the treatment of prostate cancer improves patient outcomes.

5.

Chemotherapy before surgery helps patients with nose and sinus cancer avoid debilitating eye and bone removal


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot